Segment and Geographic Area Information (Tables)
|
12 Months Ended |
Dec. 31, 2021 |
|---|
| Segment Information |
|
| Schedule of segment information - net sales and operating earnings |
| | | | | | | | | | | | | | | | | | | | | Net Sales to External Customers (a) | | Operating Earnings (a) | (in millions) | | 2021 | | 2020 | | 2019 | | 2021 | | 2020 | | 2019 | Established Pharmaceutical Products | | $ | 4,718 | | $ | 4,303 | | $ | 4,486 | | $ | 889 | | $ | 794 | | $ | 904 | Nutritional Products | | | 8,294 | | | 7,647 | | | 7,409 | | | 1,763 | | | 1,751 | | | 1,705 | Diagnostic Products | | | 15,644 | | | 10,805 | | | 7,713 | | | 6,256 | | | 3,725 | | | 1,912 | Medical Devices | | | 14,367 | | | 11,787 | | | 12,239 | | | 4,514 | | | 3,038 | | | 3,769 | Total Reportable Segments | | | 43,023 | | | 34,542 | | | 31,487 | | $ | 13,422 | | $ | 9,308 | | $ | 8,290 | Other | | | 52 | | | 66 | | | 57 | | | | | | | | | | Total | | $ | 43,075 | | $ | 34,608 | | $ | 31,904 | | | | | | | | | |
| (a) | In 2021, the impact of foreign exchange favorably impacted net sales and unfavorably impacted operating earnings. In 2020 and 2019, the impact of foreign exchange unfavorably impacted net sales and operating earnings. |
Note 15 — Segment and Geographic Area Information (Continued)
|
| Schedule of reconciliation of operating earnings to earnings from continuing operations |
| | | | | | | | | | (in millions) | | 2021 | | 2020 | | 2019 | Total Reportable Segment Operating Earnings | | $ | 13,422 | | $ | 9,308 | | $ | 8,290 | Corporate functions and benefit plan costs | | | (801) | | | (518) | | | (468) | Net interest expense | | | (490) | | | (500) | | | (576) | Loss on extinguishment of debt | | | — | | | — | | | (63) | Share-based compensation | | | (640) | | | (546) | | | (519) | Amortization of intangible assets | | | (2,047) | | | (2,132) | | | (1,936) | Other, net (b) | | | (1,233) | | | (644) | | | (651) | Earnings from Continuing Operations Before Taxes | | $ | 8,211 | | $ | 4,968 | | $ | 4,077 |
| (b) | Other, net includes integration costs associated with the acquisition of St. Jude Medical and Alere and restructuring charges in 2021, 2020 and 2019. 2021 restructuring charges include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for 2021 also includes costs related to certain litigation. Other, net in 2020 also includes costs related to asset impairments, partially offset by income from the settlement of litigation. Charges for restructuring actions and other cost reduction initiatives were approximately $375 million in 2021, $125 million in 2020 and $215 million in 2019. |
|
| Schedule of depreciation, additions to property and equipment and total assets by segment |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Additions to | | | | | | | | | | | | Depreciation | | Property and Equipment | | Total Assets | (in millions) | | 2021 | | 2020 | | 2019 | | 2021 | | 2020 | | 2019 | | 2021 | | 2020 | | 2019 | Established Pharmaceuticals | | $ | 94 | | $ | 88 | | $ | 98 | | $ | 169 | | $ | 109 | | $ | 109 | | $ | 2,789 | | $ | 2,888 | | $ | 2,858 | Nutritionals | | | 151 | | | 143 | | | 139 | | | 174 | | | 201 | | | 141 | | | 3,425 | | | 3,478 | | | 3,274 | Diagnostics | | | 760 | | | 488 | | | 403 | | | 980 | | | 1,263 | | | 726 | | | 7,699 | | | 7,696 | | | 5,235 | Medical Devices | | | 285 | | | 281 | | | 266 | | | 348 | | | 402 | | | 532 | | | 7,261 | | | 6,893 | | | 6,640 | Total Reportable Segments | | | 1,290 | | | 1,000 | | | 906 | | | 1,671 | | | 1,975 | | | 1,508 | | $ | 21,174 | | $ | 20,955 | | $ | 18,007 | Other | | | 201 | | | 195 | | | 172 | | | 201 | | | 218 | | | 160 | | | | | | | | | | Total | | $ | 1,491 | | $ | 1,195 | | $ | 1,078 | | $ | 1,872 | | $ | 2,193 | | $ | 1,668 | | | | | | | | | |
|
| Schedule of reconciliation of segment assets to total assets |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Additions to | | | | | | | | | | | | Depreciation | | Property and Equipment | | Total Assets | (in millions) | | 2021 | | 2020 | | 2019 | | 2021 | | 2020 | | 2019 | | 2021 | | 2020 | | 2019 | Established Pharmaceuticals | | $ | 94 | | $ | 88 | | $ | 98 | | $ | 169 | | $ | 109 | | $ | 109 | | $ | 2,789 | | $ | 2,888 | | $ | 2,858 | Nutritionals | | | 151 | | | 143 | | | 139 | | | 174 | | | 201 | | | 141 | | | 3,425 | | | 3,478 | | | 3,274 | Diagnostics | | | 760 | | | 488 | | | 403 | | | 980 | | | 1,263 | | | 726 | | | 7,699 | | | 7,696 | | | 5,235 | Medical Devices | | | 285 | | | 281 | | | 266 | | | 348 | | | 402 | | | 532 | | | 7,261 | | | 6,893 | | | 6,640 | Total Reportable Segments | | | 1,290 | | | 1,000 | | | 906 | | | 1,671 | | | 1,975 | | | 1,508 | | $ | 21,174 | | $ | 20,955 | | $ | 18,007 | Other | | | 201 | | | 195 | | | 172 | | | 201 | | | 218 | | | 160 | | | | | | | | | | Total | | $ | 1,491 | | $ | 1,195 | | $ | 1,078 | | $ | 1,872 | | $ | 2,193 | | $ | 1,668 | | | | | | | | | |
| | | | | | | (in millions) | | 2021 | | 2020 | Total Reportable Segment Assets | | $ | 21,174 | | $ | 20,955 | Cash and investments | | | 11,065 | | | 7,969 | Goodwill and intangible assets | | | 35,970 | | | 38,528 | All other (c) | | | 6,987 | | | 5,096 | Total Assets | | $ | 75,196 | | $ | 72,548 |
| (c) | All other includes the long-term assets associated with the defined benefit plans of $2.27 billion in 2021 and $824 million in 2020. |
|
| Schedule of net sales to external customers by geographic areas |
| | | | | | | | | | | | Net Sales to External | | | Customers (d) | (in millions) | | 2021 | | 2020 | | 2019 | United States | | $ | 16,642 | | $ | 13,022 | | $ | 11,398 | Germany | | | 2,572 | | | 2,108 | | | 1,751 | China | | | 2,392 | | | 1,965 | | | 2,346 | Japan | | | 1,695 | | | 1,386 | | | 1,435 | India | | | 1,561 | | | 1,323 | | | 1,397 | Canada | | | 1,385 | | | 841 | | | 573 | Switzerland | | | 1,313 | | | 1,140 | | | 1,068 | All Other Countries | | | 15,515 | | | 12,823 | | | 11,936 | Consolidated | | $ | 43,075 | | $ | 34,608 | | $ | 31,904 |
(d)Sales by country are based on the country that sold the product.
|